Flerie has since 2011 helped build >30 portfolio companies and had three successful exits in the life science sector. We invest in product development and commercial growth companies with a predominant focus on the biotechnology and pharmaceutical sector. Flerie became a publicly listed investment company on the Nasdaq Stockholm in June 2024.

Prokarium is a venture-backed biotech company developing microbial cancer immunotherapies and vaccines. Our team took the world's first typhoid-paratyphoid combination vaccine into the clinic, and is developing a treatment for bladder cancer to enter the clinic in 2023. The technology platform underpinning Prokarium's programs has been safely tested in 11 clinical trials in the US, UK and Vietnam in 463 volunteers including children.

Spun-out company from Cobra Biologics and established Prokarium as an independent limited company. Attracted seed-funding and follow-on funding. Initiated new collaborations and won prestigious Technology Strategy Board (now Innovate UK) grant for industrial advancements in biotechnology.

Tekiu Ltd is a knowledge transfer company in the business of facilitating different perspectives through international technical visits, delegation trips and business partnering programs. Tekiu has worked with many companies, universities and government departments across Europe to deliver high-quality experiences and to connect leaders of their fields internationally. Tekiu was a partner in the EU Horizon 2020 project 'Doing It Together science - DITOs' and was an official UK Government supplier facilitating business collaborations between the UK and Turkey under the auspice of the Newton Fund.

NorthX Biologics is a process development and manufacturing company specialising in the production of proteins, plasmid DNA, RNA and other advanced biological drugs for customers worldwide. In October 2021 the Swedish Minister of Enterprise announced NorthX Biologics as the National Innovation Hub for GMP manufacture of advanced biologics. During 2022 NorthX expanded its services into cell therapies and endeavours to be a full service ATMP and advanced biologics manufacturing partner. My role directly after the acquisition from Charles River Labs in October 2021, was to hire a new management team and sales force and establish NorthX and its brand as an independent company (while continuing as Partner in NorthX's majority shareholder Flerie).

Managed large groups of policy makers, industrialists and academics in various foresight projects, most importantly delivering a strategic national innovation plan to the Swedish Ministry of Economic Affairs.